Literature DB >> 21965663

Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.

Min-Su Jung1, Jung-Hwa Park, Young Shin Ryu, Sun-Hee Choi, Song-Hee Yoon, Mi-Yang Kwen, Ji Youn Oh, Woo-Joo Song, Sul-Hee Chung.   

Abstract

Two genes on chromosome 21, namely dual specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) and regulator of calcineurin 1 (RCAN1), have been implicated in some of the phenotypic characteristics of Down syndrome, including the early onset of Alzheimer disease. Although a link between Dyrk1A and RCAN1 and the nuclear factor of activated T cells (NFAT) pathway has been reported, it remains unclear whether Dyrk1A directly interacts with RCAN1. In the present study, Dyrk1A is shown to directly interact with and phosphorylate RCAN1 at Ser(112) and Thr(192) residues. Dyrk1A-mediated phosphorylation of RCAN1 at Ser(112) primes the protein for the GSK3β-mediated phosphorylation of Ser(108). Phosphorylation of RCAN1 at Thr(192) by Dyrk1A enhances the ability of RCAN1 to inhibit the phosphatase activity of calcineurin (Caln), leading to reduced NFAT transcriptional activity and enhanced Tau phosphorylation. These effects are mediated by the enhanced binding of RCAN1 to Caln and its extended half-life caused by Dyrk1A-mediated phosphorylation. Furthermore, an increased expression of phospho-Thr(192)-RCAN1 was observed in the brains of transgenic mice overexpressing the Dyrk1A protein. These results suggest a direct link between Dyrk1A and RCAN1 in the Caln-NFAT signaling and Tau hyperphosphorylation pathways, supporting the notion that the synergistic interaction between the chromosome 21 genes RCAN1 and Dyrk1A is associated with a variety of pathological features associated with DS.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21965663      PMCID: PMC3220559          DOI: 10.1074/jbc.M111.253971

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  55 in total

1.  Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease.

Authors:  Young Shin Ryu; So Young Park; Min-Su Jung; Song-Hee Yoon; Mi-Yang Kwen; Sun-Young Lee; Sun-Hee Choi; Chinzorig Radnaabazar; Mi-Kyoung Kim; Hangun Kim; Kwonseop Kim; Woo-Joo Song; Sul-Hee Chung
Journal:  J Neurochem       Date:  2010-08-19       Impact factor: 5.372

2.  Identification of a peptide fragment of DSCR1 that competitively inhibits calcineurin activity in vitro and in vivo.

Authors:  Betty Chan; Garrett Greenan; Frank McKeon; Tom Ellenberger
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-30       Impact factor: 11.205

3.  A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT.

Authors:  Yousang Gwack; Sonia Sharma; Julie Nardone; Bogdan Tanasa; Alina Iuga; Sonal Srikanth; Heidi Okamura; Diana Bolton; Stefan Feske; Patrick G Hogan; Anjana Rao
Journal:  Nature       Date:  2006-03-01       Impact factor: 49.962

4.  Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.

Authors:  X Altafaj; M Dierssen; C Baamonde; E Martí; J Visa; J Guimerà; M Oset; J R González; J Flórez; C Fillat; X Estivill
Journal:  Hum Mol Genet       Date:  2001-09-01       Impact factor: 6.150

5.  The kinase DYRK phosphorylates protein-synthesis initiation factor eIF2Bepsilon at Ser539 and the microtubule-associated protein tau at Thr212: potential role for DYRK as a glycogen synthase kinase 3-priming kinase.

Authors:  Y L Woods; P Cohen; W Becker; R Jakes; M Goedert; X Wang; C G Proud
Journal:  Biochem J       Date:  2001-05-01       Impact factor: 3.857

6.  DSCR1, overexpressed in Down syndrome, is an inhibitor of calcineurin-mediated signaling pathways.

Authors:  J J Fuentes; L Genescà; T J Kingsbury; K W Cunningham; M Pérez-Riba; X Estivill; S de la Luna
Journal:  Hum Mol Genet       Date:  2000-07-01       Impact factor: 6.150

7.  Renaming the DSCR1/Adapt78 gene family as RCAN: regulators of calcineurin.

Authors:  Kelvin J A Davies; Gennady Ermak; Beverley A Rothermel; Melanie Pritchard; Joseph Heitman; Joohong Ahnn; Flavio Henrique-Silva; Dana Crawford; Silvia Canaider; Pierluigi Strippoli; Paolo Carinci; Kyung-Tai Min; Deborah S Fox; Kyle W Cunningham; Rhonda Bassel-Duby; Eric N Olson; Zhuohua Zhang; R Sanders Williams; Hans-Peter Gerber; Mercè Pérez-Riba; Hisao Seo; Xia Cao; Claude B Klee; Juan Miguel Redondo; Lois J Maltais; Elspeth A Bruford; Sue Povey; Jeffery D Molkentin; Frank D McKeon; Elia J Duh; Gerald R Crabtree; Martha S Cyert; Susana de la Luna; Xavier Estivill
Journal:  FASEB J       Date:  2007-06-26       Impact factor: 5.191

8.  Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling.

Authors:  Hafiz Mohmmad Abdul; Michelle A Sama; Jennifer L Furman; Diana M Mathis; Tina L Beckett; Adam M Weidner; Ela S Patel; Irfan Baig; M Paul Murphy; Harry LeVine; Susan D Kraner; Christopher M Norris
Journal:  J Neurosci       Date:  2009-10-14       Impact factor: 6.167

9.  Phosphorylation of calcipressin 1 increases its ability to inhibit calcineurin and decreases calcipressin half-life.

Authors:  Lali Genescà; Anna Aubareda; Juan J Fuentes; Xavier Estivill; Susana De La Luna; Mercè Pérez-Riba
Journal:  Biochem J       Date:  2003-09-01       Impact factor: 3.857

Review 10.  Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1.

Authors:  Joongkyu Park; Yohan Oh; Kwang Chul Chung
Journal:  BMB Rep       Date:  2009-01-31       Impact factor: 4.778

View more
  37 in total

Review 1.  Exosome release and cargo in Down syndrome.

Authors:  Eric D Hamlett; Angela LaRosa; Elliott J Mufson; Juan Fortea; Aurélie Ledreux; Ann-Charlotte Granholm
Journal:  Dev Neurobiol       Date:  2019-08-06       Impact factor: 3.964

Review 2.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

3.  Neuronal exosomes reveal Alzheimer's disease biomarkers in Down syndrome.

Authors:  Eric D Hamlett; Edward J Goetzl; Aurélie Ledreux; Vitaly Vasilevko; Heather A Boger; Angela LaRosa; David Clark; Steven L Carroll; María Carmona-Iragui; Juan Fortea; Elliott J Mufson; Marwan Sabbagh; Abdul H Mohammed; Dean Hartley; Eric Doran; Ira T Lott; Ann-Charlotte Granholm
Journal:  Alzheimers Dement       Date:  2016-10-15       Impact factor: 21.566

Review 4.  Aberrant expression of RCAN1 in Alzheimer's pathogenesis: a new molecular mechanism and a novel drug target.

Authors:  Yili Wu; Philip T T Ly; Weihong Song
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

Review 5.  Meeting at the crossroads: common mechanisms in Fragile X and Down syndrome.

Authors:  Karen T Chang; Hyunah Ro; Wei Wang; Kyung-Tai Min
Journal:  Trends Neurosci       Date:  2013-09-25       Impact factor: 13.837

6.  Cognitive and pharmacological insights from the Ts65Dn mouse model of Down syndrome.

Authors:  Aarti Ruparelia; Matthew L Pearn; William C Mobley
Journal:  Curr Opin Neurobiol       Date:  2012-05-30       Impact factor: 6.627

7.  Phosphorylation and inactivation of glycogen synthase kinase 3β (GSK3β) by dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).

Authors:  Woo-Joo Song; Eun-Ah Christine Song; Min-Su Jung; Sun-Hee Choi; Hyung-Hwan Baik; Byung Kwan Jin; Jeong Hee Kim; Sul-Hee Chung
Journal:  J Biol Chem       Date:  2014-12-04       Impact factor: 5.157

8.  Novel and Potential Small Molecule Scaffolds as DYRK1A Inhibitors by Integrated Molecular Docking-Based Virtual Screening and Dynamics Simulation Study.

Authors:  Mir Mohammad Shahroz; Hemant Kumar Sharma; Abdulmalik S A Altamimi; Mubarak A Alamri; Abuzer Ali; Amena Ali; Safar Alqahtani; Ali Altharawi; Alhumaidi B Alabbas; Manal A Alossaimi; Yassine Riadi; Ahmad Firoz; Obaid Afzal
Journal:  Molecules       Date:  2022-02-09       Impact factor: 4.411

Review 9.  Exosomal biomarkers in Down syndrome and Alzheimer's disease.

Authors:  Eric D Hamlett; Aurélie Ledreux; Huntington Potter; Heidi J Chial; David Patterson; Joaquin M Espinosa; Brianne M Bettcher; Ann-Charlotte Granholm
Journal:  Free Radic Biol Med       Date:  2017-09-05       Impact factor: 7.376

Review 10.  Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?

Authors:  Breland Smith; Federico Medda; Vijay Gokhale; Travis Dunckley; Christopher Hulme
Journal:  ACS Chem Neurosci       Date:  2012-08-28       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.